The scope for oncology research is often high, and the sophistication of clinical trial designs and study designs is growing. Reports currently suggest that the success rate of investigational compounds approved for clinical use in cancer is the lowest of all diseases, and only 6.7 percent are expected to be approved for oncology drugs studied in Phase I studies. In oncology, there are essential differences in clinical trials. The variations are known to maximise both the clinical practise effect of cancer research and the use of restricted capital.
Subtypes of Cancer
Creation of data from oncology studies
Systematic appraisalv
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
